Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Increased adenosine-to-inosine RNA editing in rheumatoid arthritis.

Vlachogiannis NI, Gatsiou A, Silvestris DA, Stamatelopoulos K, Tektonidou MG, Gallo A, Sfikakis PP, Stellos K.

J Autoimmun. 2019 Sep 4:102329. doi: 10.1016/j.jaut.2019.102329. [Epub ahead of print]

2.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
3.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

PMID:
31383717
4.

Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications.

Xourgia E, Tektonidou MG.

J Autoimmun. 2019 Aug 1:102311. doi: 10.1016/j.jaut.2019.102311. [Epub ahead of print] Review.

PMID:
31378637
5.

Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study.

Mavrogeni SI, Markousis-Mavrogenis G, Karapanagiotou O, Toutouzas K, Argyriou P, Velitsista S, Kanoupakis G, Apostolou D, Hautemann D, Sfikakis PP, Tektonidou MG.

J Clin Med. 2019 Jul 23;8(7). pii: E1084. doi: 10.3390/jcm8071084.

6.

Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA.

Tektonidou MG, Dasgupta A, Ward MM.

Rheumatology (Oxford). 2019 Apr 22. pii: kez103. doi: 10.1093/rheumatology/kez103. [Epub ahead of print]

PMID:
31323667
7.

Mechanics of early biventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics.

Tountas C, Protogerou AD, Bournia VK, Panopoulos S, Konstantonis G, Tektonidou MG, Gournizakis A, Beldekos D, Sfikakis PP.

Clin Exp Rheumatol. 2019 Jun 4. [Epub ahead of print]

PMID:
31172928
8.

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, Tincani A, Ward MM.

RMD Open. 2019 Apr 28;5(1):e000924. doi: 10.1136/rmdopen-2019-000924. eCollection 2019. Review.

9.

Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity.

Panousis NI, Bertsias GK, Ongen H, Gergianaki I, Tektonidou MG, Trachana M, Romano-Palumbo L, Bielser D, Howald C, Pamfil C, Fanouriakis A, Kosmara D, Repa A, Sidiropoulos P, Dermitzakis ET, Boumpas DT.

Ann Rheum Dis. 2019 Aug;78(8):1079-1089. doi: 10.1136/annrheumdis-2018-214379. Epub 2019 Jun 5.

10.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.

Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION.

Semin Arthritis Rheum. 2019 May 2. pii: S0049-0172(19)30090-3. doi: 10.1016/j.semarthrit.2019.04.009. [Epub ahead of print]

PMID:
31153708
11.

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM.

Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15.

PMID:
31092409
12.

Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations.

Palli E, Kravvariti E, Tektonidou MG.

Front Immunol. 2019 Mar 15;10:487. doi: 10.3389/fimmu.2019.00487. eCollection 2019.

13.

The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.

Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, Fortin PR, Petri M, Rodriguez E, Rodriguez-Pinto I, Atsumi T, Nascimento I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, Bertolaccini ML; APS ACTION.

Thromb Res. 2019 Mar;175:32-36. doi: 10.1016/j.thromres.2019.01.010. Epub 2019 Jan 18.

PMID:
30685523
14.

Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.

Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM.

Clin Rheumatol. 2019 Jan;38(1):125-132. doi: 10.1007/s10067-018-4267-z. Epub 2018 Aug 25.

PMID:
30145635
15.

Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.

Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG.

Rheumatology (Oxford). 2018 Dec 1;57(12):2158-2166. doi: 10.1093/rheumatology/key233.

PMID:
30102390
16.

Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.

Tektonidou MG.

Front Immunol. 2018 May 31;9:1181. doi: 10.3389/fimmu.2018.01181. eCollection 2018. Review.

17.

Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort.

Panopoulos S, Bournia VK, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG.

Autoimmun Rev. 2018 Aug;17(8):816-820. doi: 10.1016/j.autrev.2018.02.008. Epub 2018 Jun 6.

PMID:
29885536
18.

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):134-141. doi: 10.1002/acr.23584.

PMID:
29669399
19.

Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.

Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Tektonidou MG.

Semin Arthritis Rheum. 2018 Jun;47(6):883-889. doi: 10.1016/j.semarthrit.2017.10.015. Epub 2017 Oct 23.

PMID:
29150207
20.

Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016.

Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM.

Ann Rheum Dis. 2017 Dec;76(12):2009-2016. doi: 10.1136/annrheumdis-2017-211663. Epub 2017 Aug 9. Review. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

PMID:
28794077
21.

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, Tektonidou MG; APS ACTION.

Lupus. 2018 Mar;27(3):399-406. doi: 10.1177/0961203317724219. Epub 2017 Aug 1.

PMID:
28764618
22.

Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015.

Tektonidou MG, Ward MM.

J Rheumatol. 2017 May;44(5):626-630. doi: 10.3899/jrheum.160546. Epub 2017 Feb 15. Review.

23.

Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.

Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A.

Autoimmun Rev. 2017 Mar;16(3):308-312. doi: 10.1016/j.autrev.2017.01.009. Epub 2017 Jan 29.

PMID:
28147263
24.

Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012.

Tektonidou MG, Wang Z, Ward MM.

Arthritis Rheumatol. 2016 Nov;68(11):2680-2685. doi: 10.1002/art.39758.

25.

Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis.

Tektonidou MG, Dasgupta A, Ward MM.

Arthritis Rheumatol. 2016 Jun;68(6):1432-41. doi: 10.1002/art.39594. Review.

26.

Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging.

Mavrogeni SI, Sfikakis PP, Kitas GD, Kolovou G, Tektonidou MG.

Semin Arthritis Rheum. 2016 Apr;45(5):611-6. doi: 10.1016/j.semarthrit.2015.09.005. Epub 2015 Oct 8. Review.

PMID:
26616201
27.

Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011.

Tektonidou MG, Wang Z, Dasgupta A, Ward MM.

Arthritis Care Res (Hoboken). 2015 Aug;67(8):1078-85. doi: 10.1002/acr.22575.

28.

Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: a report from a south-eastern European Expert Meeting.

Ntali S, Damjanov N, Drakakis P, Ionescu R, Kalinova D, Rashkov R, Malamitsi-Puchner A, Mantzaris G, Michala L, Pamfil C, Rednic S, Tektonidou MG, Tsiodras S, Vassilopoulos D, Vojinovic J, Bertsias GK, Boumpas DT.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):959-68. Epub 2014 Nov 7. Review.

PMID:
25436516
29.

Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance.

Georgiadou SP, Gamaletsou MN, Mpanaka I, Vlachou A, Goules AV, Ziogas DC, Syriou V, Tektonidou MG, Kaltsas G, Manoussakis MN, Sipsas NV.

Clin Infect Dis. 2015 Mar 15;60(6):868-74. doi: 10.1093/cid/ciu938. Epub 2014 Nov 24.

PMID:
25422387
30.

Identification and treatment of APS renal involvement.

Tektonidou MG.

Lupus. 2014 Oct;23(12):1276-8. doi: 10.1177/0961203314538687.

PMID:
25228725
31.

14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.

Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD.

Autoimmun Rev. 2014 Jun;13(6):685-96. doi: 10.1016/j.autrev.2014.01.053. Epub 2014 Jan 24. Review.

PMID:
24468415
32.

Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).

Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, Gordon C, Ruiz-Irastorza G, Egurbide MV, Gil A, Espinosa G, Houssiau F, Rahman A, Martin H, McHugh N, Galindo M, Akil M, Amigo MC, Murru V, Khamashta MA.

Rheumatology (Oxford). 2014 Feb;53(2):275-84. doi: 10.1093/rheumatology/ket313. Epub 2013 Oct 4.

PMID:
24097288
33.

Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis.

Konsta M, Bamias G, Tektonidou MG, Christopoulos P, Iliopoulos A, Sfikakis PP.

Rheumatology (Oxford). 2013 Mar;52(3):448-51. doi: 10.1093/rheumatology/kes316. Epub 2012 Nov 30.

PMID:
23204549
34.

Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.

Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP.

J Rheumatol. 2012 Jan;39(1):60-2. doi: 10.3899/jrheum.110617. Epub 2011 Dec 1.

PMID:
22133618
35.

Validation of new biomarkers in systemic autoimmune diseases.

Tektonidou MG, Ward MM.

Nat Rev Rheumatol. 2011 Nov 1;7(12):708-17. doi: 10.1038/nrrheum.2011.157. Review.

36.
37.

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations.

Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y.

Lupus. 2011 Feb;20(2):174-81. doi: 10.1177/0961203310395052.

PMID:
21303834
38.

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y.

Lupus. 2011 Feb;20(2):165-73. doi: 10.1177/0961203310395051.

PMID:
21303833
39.

Presence of other autoimmune diseases in subjects with autoimmune thyroid disease.

Tektonidou MG.

Am J Med. 2010 Oct;123(10):e23; author reply e25. doi: 10.1016/j.amjmed.2010.03.030. No abstract available.

PMID:
20920677
40.

Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey.

Louie GH, Tektonidou MG, Caban-Martinez AJ, Ward MM.

Arthritis Care Res (Hoboken). 2011 Feb;63(2):247-60. doi: 10.1002/acr.20362.

41.

Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases.

Tektonidou MG, Ward MM.

Arthritis Res Ther. 2010;12(5):R179. doi: 10.1186/ar3143. Epub 2010 Sep 27.

42.

MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.

Tektonidou MG.

Lupus. 2010 Sep;19(10):1243-5. doi: 10.1177/0961203310367659. Epub 2010 May 25.

PMID:
20501524
43.

Measures of psychological distress in patients with arthritis: comment on the article by Fuller-Thomson and Shaked.

Caban-Martinez AJ, Louie GH, Ward MM, Tektonidou MG.

Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):140-1; author reply 141-2. doi: 10.1002/acr.20030. No abstract available.

44.

Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV.

Emerg Infect Dis. 2009 Jun;15(6):956-9. doi: 10.3201/eid1506.090101. Review.

45.

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM.

Arthritis Rheum. 2009 Jan 15;61(1):29-36. doi: 10.1002/art.24232.

46.

Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Tektonidou MG.

Clin Rev Allergy Immunol. 2009 Jun;36(2-3):131-40. doi: 10.1007/s12016-008-8112-z. Review.

PMID:
19048414
47.

Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS.

Tektonidou MG, Sotsiou F, Moutsopoulos HM.

J Rheumatol. 2008 Oct;35(10):1983-8. Epub 2008 Aug 1.

PMID:
18688914
48.

Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis.

Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN.

Clin Rheumatol. 2008 Jun;27(6):795-7. doi: 10.1007/s10067-008-0855-7. Epub 2008 Feb 28.

PMID:
18305977
49.

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

Tektonidou MG, Skopouli FN.

Clin Rheumatol. 2008 Apr;27(4):541-2. Epub 2007 Oct 26.

PMID:
17963018
50.

Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution.

Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM.

Am J Med. 2007 Jul;120(7):636-42.

PMID:
17602939

Supplemental Content

Loading ...
Support Center